10th Cytokines and Inflammation Conference (CI)
|Event Date/Time: Jan 30, 2012||End Date/Time: Jan 31, 2012|
|Abstract Submission Date: Dec 30, 2011|
In 2012, the conference will cover ever-important topics such as the TNF family, the inflammasome, chemokines, costimulation and innate immunity. In addition, timely coverage will be devoted to areas of current rapid expansion, such as the IL-17 and Th17 fields and JAK/STAT kinases, at a time when phase 2 and even phase 3 studies are being conducted and reported in these areas. Intriguing recently discovered cytokines, such as IL-25, novel alarmins and novel IL-1 family members will also be covered.
A disease focus will intersect the target-centric presentations with emphasis on autoimmunity, cancer and hematologic disorders, bone and cholesterol metabolisms, obesity and infectious diseases. The conference will also cover technological advances in cytokine biology such as bispecific antibodies, latent cytokines, vaccines and cytokine delivery by commensal bacteria.
As usual, poster sessions and opportunities for networking will complement the great roster of distinguished speakers. The organizations participating are a great selection of innovative medical organizations from academia (NIH, UCLA, UCSD, Cleveland Clinic, La Jolla Institute, Virginia Commonwealth U, U Mass, City of Hope, Scripps, Barts and the London), industry (Amgen, Pfizer, MedImmune, Novartis, Centocor/Johnson and Johnson, Biogen Idec, Incyte, Genentech, Genzyme, Chemocentryx) and, last but not -by any means- least, the US FDA.
Sessions of the conference include:
Session I: Cytokines Regulation
Session II: Cytokine and Chemokine Signaling
Session III: Cytokines in Health and Disease
Session IV: Translational Medicine
Session V: Inflammation and Cancer
Session VI: Novel Technological Developments in Cytokines
Session VII: Therapeutic Applications of Cytokines and Chemokines
This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
1) 4th Immunotherapeutics and Immunomonitoring
2) Immunotherapeutics Partnering and Dealmaking
3) Allergy Drug Discovery and Development